{"schema_version":"secwatch.filing_event.v1","accession":"0001739410-25-000052","form_type":"8-K","ticker":"RLYB","cik":"0001739410","company_name":"Rallybio Corp","filed_at":"2025-04-08T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.526759+00:00","generated_at":"2026-05-23T19:05:50.572163+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Rallybio discontinues RLYB212 for FNAIT after Phase 2 PK misses efficacy targets","bullets":["Phase 2 PK results: RLYB212 concentrations near/ below assay LLoQ, missing minimum target of 3 ng/mL and predicted 6-10 ng/mL.","No further enrollment; safety follow-up of sentinel participant continues; dose adjustment not feasible.","RLYB116 confirmatory PK/PD study to initiate Q2 2025 with data from Cohorts 1 and 2 in 3Q/4Q 2025.","REV102 (ENPP1 inhibitor, JV with Recursion) in IND-enabling studies; Phase 1 expected 2026; preclinical data 2H 2025.","RLYB332 (long-acting matriptase-2 antibody) preclinical development ongoing for iron overload diseases."],"urls":{"canonical":"https://secwatch.observer/filing/0001739410-25-000052","json":"https://secwatch.observer/filing/0001739410-25-000052.json","markdown":"https://secwatch.observer/filing/0001739410-25-000052.md","text":"https://secwatch.observer/filing/0001739410-25-000052.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1739410/000173941025000052/0001739410-25-000052-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1739410/000173941025000052/rlyb-20250408.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-23T19:05:50.572163+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}